C oronary artery disease (CAD) remains a significant healthcare concern despite improvements in preventative strategies and therapeutic possibilities. The majority of sudden ischemic coronary events are precipitated by rupture of a bulky, lipid-rich atheromatous plaque, resulting in the development of intraluminal thrombosis and downstream myocardial injury. Precursor lesions that share similar morphological features to ruptured plaques can be reliably identified using intravascular imaging modalities.
Study Selection
Study characteristics for inclusion were as follows: (1) patients with stable cardiovascular disease; (2) assessment of plaque characteristics, including plaque morphology (calcified, noncalcified, and partially calcified) and assessment of individual HRP features, including low-attenuation plaque, napkin-ring sign, spotty calcification, and positive remodeling; (3) evaluation of the association between plaque characteristics and future MACE; (4) clinical follow-up of at least 1 year after CTCA; and (5) fully published status. We excluded studies that included patients presenting with acute coronary syndrome undergoing CTCA assessment, studies evaluating coronary artery calcium score without specific lesion assessment, studies including asymptomatic patients, and studies that included elective revascularization as part of their definition of MACE. Details on the clinical indication for CTCA for each included study are presented in Table II in the Data Supplement. Where multiple studies reported on the same cohort of patients, we only included articles with the longest clinical follow-up and largest cohort size.
Data Items and Collection Process
Data items to be collected were specified before conducting the literature search. Items for data extraction included study design; clinical rationale for CTCA; patient baseline characteristics; and definitions of plaque morphology, HRP features, and MACE. We defined plaque morphology and HRP features according to the definitions adopted by each individual study. For HRP features, low-attenuation plaque was most commonly defined as plaque with density ≤30 HU, although 1 study used a threshold of ≤38 HU. 9 Napkin-ring sign was generally defined as the presence of a plaque core with low computerized tomographic (CT) attenuation surrounded by a rim-like area of higher attenuation. Spotty calcification was either defined as a limit in visualized calcification (<2-3 mm) or as a proportion of the vessel dimensions (length of calcium deposit <3/2 of vessel diameter and width of <2/3 of vessel diameter). Full definitions of plaque morphology and HRP features across studies are detailed in Tables III and IV in the Data Supplement, respectively. Data were also collected on CAD burden at baseline as determined by coronary artery calcium score 10 and proportion of patients with obstructive CAD (≥50% luminal stenosis), follow-up completion, and clinical outcomes. Two investigators (N.N. and F.J.H.) independently conducted the literature search, and 3 investigators (F.J.H, C.C., and H.R.) performed the data extraction. Eligible studies and extracted data were verified by the senior author (A.J.B) with any discrepancies resolved by consensus. Risk of bias within individual studies were evaluated according to the NewcastleOttawa scale (Table V in the Data Supplement).
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Clinical End Points
The primary end point of this study was the association between plaque composition (calcified, noncalcified, and partially calcified) and subsequent MACE. Study-specific definitions of MACE were used for all analyses. In 4 studies, MACE was defined as the composite of cardiac death and nonfatal MI, [12] [13] [14] [15] with 9 studies also including unstable angina requiring either hospitalization 9, [16] [17] [18] [19] or revascularization [20] [21] [22] [23] in their MACE definition. One study did not include death from any cause in their MACE definition 22 (ie, composite of nonfatal myocardial infarction and unstable angina), whereas another study used all-cause death instead of cardiac death. 20 Secondary end points included the associations between specific HRP features on CTCA and subsequent MACE.
Statistical Analysis
Data concerning hazard ratio (HR) and 95% confidence intervals (CI) of plaque characteristics and risk of future MACE were extracted and log-transformed, with preference for the HR from the most adjusted model. Full details on the extracted HR and variables used within each model are provided in Table VI in the Data Supplement. Data were analyzed by random-effects modeling for the primary end point and individual secondary end points to produce overall summary estimates with 95% CI. Statistical heterogeneity was quantified using the I 2 statistic and quantified as low (<25%), moderate (<50%), or high (>75%). 24 Publication bias was assessed visually by funnel plots and by the Egger test. Sensitivity analyses were performed to explore the effect of systematic exclusion of individual studies to assess for changes in the pooled estimates. Subgroup analysis was performed with studies stratified by clinical end points (studies including and excluding revascularization), Asian versus non-Asian subjects, and using a 64-detector row threshold. A 2-sided P value <0.05 was considered significant. All statistical analyses were conducted using StataMP 14.0 (Stata Corp LP, College Station, TX).
Results
A total of 5496 potential citations were screened, with 72 studies identified for potential inclusion and further evaluation. Of these, 59 studies were excluded because they did not specifically evaluate CTCA plaque morphology or HRP features (38 studies), the study patients underwent CTCA for suspected acute coronary syndrome (7 studies), the outcomes reported did not include MACE (7 studies), the definition of MACE included elective coronary revascularization (5 studies), or studies failed to report HRs for individual HRP components or reported on the same patient cohort (2 studies). Full identification and process of study exclusion are detailed in the PRISMA flow diagram (Figure 1 ).
Thirteen studies with a total of 13 977 patients met the prespecified inclusion criteria and were included in the final quantitative analysis. 9, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] The study period ranged from 2002 to 2011 with 9 prospective studies and 4 studies of retrospective design. The reason for undergoing CTCA was predominantly for suspected CAD (11 studies), although patients with known CAD (eg, postcoronary intervention excluding bypass grafting) were included in 2 studies. 16, 22 Further details of study design and baseline demographics are presented in Table 1 .
The slice capability on multidetector computed tomography (MDCT) varied between studies, with 12 studies using 64-slice MDCT, 2 studies using 16-slice MDCT, and 1 study using 4-slice MDCT (some studies used multiple, different MDCT scanners with different slice capability). The presence of obstructive CAD identified by CTCA ranged from 0% to 38% in individual study cohorts. Further details of CT characteristics can be found in Table 2 and Table VII 
Clinical Outcomes
In total, 552 (3.9%) MACE occurred in 13 977 patients with mean study follow-up ranging from 1.3 to 8.2 years. MACE Figure 1 . Study flow chart. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram illustrating the study selection process for the systematic review and meta-analysis. ACS indicates acute coronary syndrome; CTCA, computed tomographic coronary angiography; and MACE, major adverse cardiovascular events. involved cardiac death in 112 patients, nonfatal myocardial infarction in 330 patients, and unstable angina requiring hospitalization or revascularization in 110 patients. Full MACE breakdown for each study are presented in Table 3 .
Plaque Morphology and MACE
Nine studies reported outcome data on the association between CTCA plaque morphology and MACE, with 8 studies reporting data on noncalcified plaque, 7 on calcified plaque, and 8 on partially calcified plaque subtypes. The strongest association between CTCA plaque morphology and MACE was observed in noncalcified plaque with an overall HR of 1 Figure 2 . In sensitivity analyses, there were no marked differences in the pooled HR for each plaque subtype when the analysis was stratified by those studies including revascularization in their MACE definition, studies using <64-slice MDCT, nor when considering Asian versus non-Asian patient populations (Figures I through III in the Data Supplement, respectively). Similarly, systematic exclusion of individual studies did not 
HRP Features and MACE
Six studies assessed the secondary end points of the presence of specific HRP features and risk of future MACE, with 6 studies reporting outcomes on low-attenuation plaque, 5 on napkin-ring sign, 2 on spotty calcification, and 6 on positive remodeling. Full details of the included studies are provided in Table 2 , with the prevalence of individual HRP features summarized in Table 4 
Discussion
To our knowledge, this is the first meta-analysis to evaluate the association between CTCA-defined plaque characteristics and subsequent MACE. For plaque morphology, we find that the strongest association occurred with noncalcified plaque, with the risk of subsequent clinical events reducing as plaque calcification increases. We also find that all established HRP features are associated with MACE, with the strongest association observed for lesions with the napkin-ring sign. These results demonstrate that the reporting of CTCA-defined plaque characteristics has potential to inform clinicians in the risk stratification of patients.
Pathological studies have established that lipid-rich fibroatheroma are responsible for the majority of ischemic coronary events through plaque rupture and subsequent intraluminal thrombosis. 25 Prospective human studies have reaffirmed this observation, demonstrating an independent association between the presence of thin-cap fibroatheromata and future MACE. 2 Our study is consistent with these observations and again highlights that the risk of MACE is highest in noncalcified plaques, which are generally composed of a mixture of lipid-rich and fibrous material. Although detailed analysis of plaque composition is challenging within the spatial resolution of CTCA, lower plaque attenuation values have previously correlated with necrotic core and fibrofatty tissue on virtual histology intravascular ultrasound imaging. 26 Thus, low-attenuation plaques should theoretically have a high proportion of extracellular lipid content. Our data would again be consistent with this because we find a stronger association between low-attenuation plaques and MACE, when compared with noncalcified plaque. Taken together, these data suggest that interpretation of CTCA-defined plaque morphology may impart important prognostic information independent of established calcium-scoring algorithms.
Our data again highlights a potentially discrepant relationship between coronary calcification and future cardiovascular risk. On one hand, previous observational studies have consistently demonstrated that the risk of future cardiovascular events is progressively increased with higher coronary artery calcium scores. 27 However, our pooled results suggest that calcified plaques have the weakest association with MACE, whereas the risk of future events was more than doubled if a lesion displayed evidence of spotty calcification. These data would, therefore, suggest that the pattern and extent of intimal calcification may be an important determinant of risk. Biomechanical models have suggested that small, microscopic calcific deposits in the fibrous cap and plaque architecture can act to amplify plaque structural stress, acting as a possible driver for plaque rupture. 28, 29 However, as calcification becomes more extensive, the macroscopic plates of calcification can act as a stress shield, protecting the plaque from high mechanical loading. 30 Support for this theory has also emerged from recent data highlighting that statins may promote plaque stabilization through progressive macroscopic intimal calcification. 31 Further studies are now required to ascertain the role of calcification in plaque destabilization and to assess whether the mechanisms that promote intimal calcification can be induced in an effort to improve clinical outcomes.
We find that each prespecified HRP feature in our analysis was strongly associated with MACE and that there was an incremental risk when ≥2 HRP features were present within the same plaque. Although the presence of multiple 9,18 similar results were reported by a large prospective study. 6 In this study, plaques with low-attenuation, positive remodeling, or both features were a significant predictor of the development of future acute coronary syndrome (adjusted HR, 8.24; 95% CI, 5.26-12.96). These data imply that future cardiovascular risk could be higher in patients who demonstrate multiple HRP features or even multiple plaques with HRP features. Further prospective studies are now required to assess whether CT-defined HRP features can be used to guide pharmacological strategies in an effort to improve clinical outcomes in a manner that is economically viable.
Positive predictive value (PPV) was not uniformly reported by the studies in our analysis, and when it was described, estimates were at a segmental level, and the inference at a patient-level remains unclear. In addition, the quoted PPV for individual plaque characteristics were discrepant between studies and were likely influenced by the low prevalence of HRP features in patients with stable symptoms because PPV is influenced by disease prevalence such that, when prevalence is low, so too is PPV. For example, in the study by Otsuka et al, 23 the prevalence of HRP segments was 24%, and the associated PPV for MACE was 86%. Conversely, in another analysis by the same group, 17 the prevalence of napkin-ring sign was 0.4%, yielding a PPV of 22%. Currently, there is no recommendation on the management of individual HRP features or whether these patients require more aggressive risk factor treatment. Plaque burden and stenosis severity are well-established markers of prognosis, and it is hypothesized that HRP may simply be a marker of greater atherosclerotic burden. 32 Although no studies have reported HRP significance over plaque extent, in our pooled sensitivity analysis of studies that adjusted for obstructive stenosis, HRP presence was independently associated with MACE. These results should encourage the requirement for a uniform reporting system such as CAD-Reporting and Data System that incorporates HRP; however, it should also include plaque morphology and disease extent as well. 7 Application of these parameters both in clinical practice and the research literature will overcome inconsistencies encountered in pooling data and allow future studies to ascertain the true independent effect of HRP on patient prognosis.
Study Limitations
There are certain limitations to our analysis that should be considered when interpreting the findings. First, the included studies have used variable definitions for plaque morphology and specific HRP features that will have introduced a degree of heterogeneity into the analysis. However, the differences in definitions were modest and are unlikely to affect the overall biological association between plaque characteristics and clinical outcomes. Second, CT technology also varied between studies, which may have affected the interstudy reliability for the assessment of plaque morphology and influenced the prevalence of HRP identified. Although the majority of our studies reported outcomes at a patient-level, segment-based risk estimates were used for 2 studies, 17, 23 and inclusion of these data may have had subtle effects on the overall pooled estimates. We had no access to patient-or segment-level data and were, therefore, unable to directly quantify any incremental prognostic information provided by plaque characterization over other known CTCA-derived markers of risk, including stenosis severity and atheroma volume. Unstable angina requiring either revascularization or hospitalization was also part of the MACE definition in 9 included studies, which may limit ascertainment of the relative prognostic value of HRP versus stenosis severity. Finally, although some studies suggest that HRP is a predictor of MACE, independent of stenosis, the data do not demonstrate that HRP is a stronger predictor than significant stenosis, and most data suggest that it may not be. Given this limitation and the fact that the PPV is low, it remains unclear whether HRP reporting may have management implications.
Conclusions
Our data demonstrate that HRP is most likely an independent predictor of MACE, which supports the inclusion of HRP reporting in clinical practice. However, at this point, it remains unclear whether HRP reporting may have clinical implications. 
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